Systemic Mastocytosis is a rare condition characterized by the abnormal proliferation of Mast Cells. Presentation as a solitary vertebral body lesion is extremely uncommon and may be confused with more ominous conditions such as metastasis. Familiarity with the condition can heighten clinical suspicion, direct tissue diagnosis, guide management and indicate appropriate follow up. We present a case of a 64-year-old woman undergoing staging for recently diagnosed breast cancer who was found to have Systemic Mastocytosis of a single vertebral body.
CASE REPORT
A 64 year old woman was referred to our radiology department for evaluation of a palpable right breast mass. Diagnostic mammogram showed a spiculated mass in the right upper outer quadrant (Figure 1a and 1b) . Targeted ultrasound demonstrated an irregularly-shaped hypoechoic mass at the 10 o'clock position, highly suspicious for malignancy (Figure 2 ). Core needle biopsy revealed infiltrating, moderately differentiated ductal carcinoma. Sentinel lymph node biopsy was positive for adenocarcinoma. On metastatic workup, a Tc99m MDP bone scan demonstrated a unifocal, horizontally oriented focus of increased radiotracer uptake at the T10 vertebral body (Figure 3) . Correlation with available radiographs demonstrated no osseous abnormality at that site ( Figure 4 ). An FDG PET/CT demonstrated heterogeneous osteosclerosis without significant FDG avidity (Figures 5-7 ). There was no evidence of visceral involvement. The presence of a single non-FDG avid metastatic focus remained of primary concern. Because such a finding would significantly alter treatment options and prognosis (upstaging the patient to stage IV), tissue sampling was deemed necessary. She was referred for CT guided biopsy of the T10 vertebral body (Figure 8 ). Pathology showed extensive proliferation of spindle mast cells confirmed by immunophenotype (positive for CD117, CD25, and mast cell tryptase), satisfying the WHO diagnostic criteria for Systemic Mastocytosis (Figures 9-11) . She did report a recent fall that aggravated her chronic low back pain although she did not seek treatment. She reported no other recent illnesses or hospitalization. The patient's past medical history included hyperlipidemia, but she denied any history of hypersensitivity, urticaria or allergies. Physical examination revealed an afebrile woman with blood pressure of 145/78, heart rate of 76 beats per minute without palpable organomegaly or other abnormality. Lab evaluation with Complete Blood Count (CBC), Basic Metabolic Panel (BMP), Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) were unremarkable. DEXA scan demonstrated osteopenia. Treatment was initiated for T2N1M0 breast cancer. In the absence of systemic symptoms, no treatment of her Systemic Mastocytosis was given.
Etiology and Demographics
Systemic Mastocytosis (SM) is a rare condition with an incidence of 5-10/100,000 per year [1] . Seven World Health Organization variants have been described [2] . These range from a benign Mastocytic Tumor to myeloproliferative leukemia [2] . Seventy five percent of cases are diagnosed in children as Urticaria Pigmentosa (UP) with a peak incidence of 2 years [3] . The most commonly encountered form in adults is the Indolent Type (Indolent System Mastocytosis) with a median age of 49 years at diagnosis [4] . There is no gender predilection [4] . Pathogenesis appears to result from abnormal mast cell proliferation due to a random mutation in the kit gene [5] .
Clinical and Imaging Findings
Diagnosis of Systemic Mastocytosis depends on fulfillment of one major and one minor or 3 minor WHO criteria [1] . The major criterion is the presence of multifocal dense mast cell infiltrates in one or more extra-cutaneous organs, most commonly the bone marrow. Minor criteria include the following: i) abnormal morphology of extracutaneous mast cells (spindle-shaped cells); ii) increased serum tryptase level (>20 ng/ml); iii) abnormal expression of CD2 and/or CD25 on bone marrow mast cells; iv) detection of a kit mutation at codon 816 in an extra-cutaneous organ [6] . Our patient was classified as Isolated Bone Marrow Mastocytosis (BMM) subtype in the absence of cutaneous symptoms. Interestingly, she denied symptoms of mast cell degranulation (bronchospasm, anaphylaxis, atopy) seen in 86% of patients with this variant [2] . Assessment for kit mutation was not undertaken as the tissue specimen was sufficient for the diagnosis (dense mast cell aggregates with abnormal CD25 expression).
Symptomatology is widely variable and dependent on the WHO type. The most commonly involved organ is the skin with pruritus, erythema or orticaroid lesions erupting with mechanical stress (Darier's sign) [6] . Physical disfigurement may lead to development of neurosychiatric symptoms such as depression and even suicidal ideation [7] . Skeletal manifestations are present in up to 70% of SM cases as osteopenia, bone pain and insufficiency fractures [9] . Bone marrow infiltration, if diffuse, may lead to pancytopenia [6] . Visceral involvement most commonly affects the lymph nodes, liver and spleen and presents with organomegaly [2]. Frank organ failure is possible, typically associated with more aggressive forms of the condition [1]. Peptic ulcer disease, abdominal pain and diarrhea have also been described as Mastocytosis Enterocolitis [10] . As the result of mast cell degranulation, anaphylaxis, hypotension and syncope can occur especially in the setting of physical stress [6] . Laboratory tests including an elevated serum tryptase (>20ng/ml -1 ) can be helpful as one of the minor criteria [11] . Blood counts are important in monitoring for progression to bone marrow suppression or leukemia [7] . Peripheral eosinophilia is seen in up to 20% of cases [7] . Other lab values, including a normal ESR and CRP, may be useful in ruling out other conditions such as osteomyelitis. Because of the wide variability and non-specificity of symptoms, the diagnosis may be elusive on clinical grounds alone as symptoms can be seen in a variety of more common conditions [12] .
Radiographic findings have been reported in up to 70% of patients with SM [13] . The most commonly encountered pattern is that of diffuse osteoporosis and osteopenia, believed to result from heparin production by mast cells [14] . Osseous demineralization can be monitored with DEXA scans [2] . Ill defined, discrete, sclerotic lesions of varying shapes asymmetrically distributed throughout the axial and appendicular skeleton characterize another presentation, and can be mistaken for metastatic disease [15] . Frenzel reported a case of a SM presenting with the "Ivory Verytebra Sign" i.e densely sclerotic vertebral body which is more commonly seen with metastatic disease or osteomyelitis. [16] . Although frequently involved, skeletal lesions are not part of the diagnostic criteria [6] .
CT findings of skeletal involvement resemble those of radiographs [13] . Although no specific CT signs exist, it offers superior resolution and can aid in differentiating SM from other disorders. Cross sectional imaging has the added benefit of imaging visceral manifestations of SM such as hepatosplenomegaly, and retroperitoneal and mesenteric adenopathy [17] . Despite her recent trauma, our patient had intact vertebral bodies without a linear lucency or cortical disruption to suggest a fracture. The absence of vertebral body trabeculations and sparing of the posterior elements made the diagnosis of Paget's disease less likely. The intact endplates ruled out a Schmorl's node. Preservation of the soft tissue planes immediately surrounding the vertebral body argued against osteomyelitis.
Findings of SM on MRI are nonspecific but may visualize bone marrow infiltration by mast cells. A mosaic pattern of low to intermediate signal on T1 and intermediate to hyperintense signal on T2 weighted images has been described [18, 30] . Since there is no correlation between bone marrow signal changes and mast cell percentage in bone marrow biopsy, prospective suspicion of SM on MRI would be difficult [18] . Contrast enhancement is not typically seen with SM and, when present, should argue for an alternative diagnosis such as metastasis or Sarcoidosis [19] . An MRI was not felt to be indicated in our patient as definitive tissue sampling would ultimately be necessary given the clinical and prognostic implications associated with the presence of a distant metastatic focus (Stage IIB versus Stage IV).
Scintigraphy with Tc99 methylene disphosphonate (MDP) is more sensitive to osseous involvement than radiographs with up to 74% of SM patients demonstrating abnormal uptake [20] . The activity pattern varies and can include diffuse osseous uptake producing a "superscan" [21] . Unifocal uptake is much less common. In a study of 75 patients with SM, only 2 patients had uptake at a solitary site [21] . Focal Tc99m MDP uptake of a single vertebral body as in our patient (the so called "Black Ivory Sign") has yet to be described for SM [22] . The most commonly encountered pathology is focal metastasis followed by acute compression fracture, Paget's disease and Lymphoma [22] . Scintigraphy can be used to DISCUSSION assess disease progression in SM, even before the development of systemic symptoms or bone marrow findings [21] . Serial bone scans offer an efficient and effective alternative to cross sectional monitoring and have prognostic value, as patients with more extensive osseous involvement carry a worse prognosis [10] .
The use of FDG-PET/CT in SM has been limited to a small number of cases [23] . Findings are similar to other myeloproliferative disorders, demonstrating no significant visceral or osseous FDG avidity [23, 24] . The presence of FDG avidity would argue for an alternative diagnosis such as metastasis. Although FDG-PET/CT has demonstrated excellent efficacy in detecting bony metastasis in breast cancer patients, its sensitivity is degraded with smaller primary breast lesions and sclerotic bony metastasis [31] . In our case, a non-FDG avid metastatic focus required exclusion and therefore tissue sampling was deemed necessary.
Treatment and Prognosis
There are no curative therapies for SM. Symptomatic treatment with antihistamines, Disodium cromolyn, or leukotriene inhibitors provides good control in patients with mild symptoms [25] . Immunomodulators (prednisone, azathioprine, methotrexate, cyclosporine) could also be considered in patients, with formularies and combinations tailored to each patient [25] . Patients should be counseled to avoid triggers such as systemic stress. Epinephrine should be reserved for life threatening anaphylaxis [1]. Omalizumab is an effective antagonist to the IgE mediated symptoms reserved for patients who fail first line therapy [26] . Bisphosphonates have been proven safe in SM for treatment of patients with osteoporosis [27] .
Cytoreductive agents (Interferon alpha (IFN), 2 Chlorodeoxyadenosin (2CdA), Fludarabine, Cytarabine, Mitoxantrone) are reserved for symptoms refractory to basic therapy with identifiable changes in hematologic profile [28] . Tyrosine Kinase Inhibitors (Imatinib, Dasatinib and Midostaurin) have also undergone evaluation although reports of their usefulness are limited [29] . Bone marrow transplant may offer a last resort [29] .
Prognosis depends on the disease subtype. Children diagnosed with the condition typically see resolution by adolescence [2] . Aggressive forms have a 1% per year risk of leukemic transformation or development of concurrent lymphoma and carry a prognosis of less than 6 months [2]. Those with systemic involvement have a median survival of 5 years [3] . Close monitoring of disease progression using bone scan and serum tryptase levels can help identify systemic progression at an early stage and indicate cytoreductive or chemotherapeutic agents [29] .
Differential Diagnosis
In the absence of typical cutaneous symptoms, the nonspecificity of clinical and imaging findings makes the differential diagnosis of SM quite broad. In the setting of isolated bone uptake on bone scan, differential considerations can be trimmed substantially, although tissue sampling is usually required for definitive diagnosis. The most important distinction is from sclerotic metastasis as the result of lung, breast or prostate cancer [30] . Trauma, infection and arthropathy are other common conditions that warrant consideration. A review of the differential diagnosis for a single Tc99m-MDP avid vertebral body is provided in table 1.
Systemic Mastocytosis is a rare myeloproliferative disorder that can have visceral, cuteaneous and osseous manifestations. Imaging findings are non specific and laboratory/ pathologic evaluation of a tissue sample is required for diagnosis. Systemic Mastocytosis presenting as focal Tc99m-MDP radiotracer uptake of a solitary vertebral body is extremely uncommon and may be confused with more ominous conditions such as metastasis. The use of serial Tc99m-MDP bone scans is a practical means of monitoring disease burden and has prognostic indications. 
